Emergent Biosolutions EBS Total debt

Total debt at other companies

Thermo Fisher ScientificTMO

$39.18B+4.6%

Regeneron PharmaceuticalsREGN

$2.71B+0.1%

SIGA TechnologiesSIGA

$439.4K-58.8%

AMP

Amphastar PharmaceuticalsAMPH

$688.51M+5.0%

Amneal Pharmaceuticals, Inc.AMRX

$2.57B+18.0%

Lifecore Biomedical, Inc.LFCR

$8.06M—

FAQ

What is Emergent Biosolutions's total debt?

Emergent Biosolutions (EBS) reported total debt of $588.2M in Q2 2026.

How has Emergent Biosolutions's total debt changed year-over-year?

Emergent Biosolutions's total debt decreased by 13.0% year-over-year, from $676.1M to $588.2M.

What is the long-term trend for Emergent Biosolutions's total debt?

Over 5 years (2020 to 2025), Emergent Biosolutions's total debt has grown at a -8.5% compound annual growth rate (CAGR), from $908M to $583.7M.

What does total debt mean?

Total debt represents the aggregate sum of all interest-bearing financial obligations, including short-term borrowings, the current portion of long-term debt, and long-term debt instruments. It also encompasses capitalized lease liabilities and other debt-like financing arrangements that require fixed repayment schedules. This metric serves as a comprehensive indicator of a company's total financial leverage and its reliance on external capital providers.